



## **Tokushima University to Collaborate with SOCIUM Inc. Strategic partnership aims to AI-driven drug discovery for Rare Gastrointestinal Tumor**

SOCIUM Inc. announced that SOCIUM Inc. (Head office: Chuo-ku, Tokyo, CEO: Dr. Hiroshi Kawai) has entered into a joint research agreement with Tokushima University Graduate School of Biomedical Sciences (Tetsuji Takayama, Professor, Department of Gastroenterology and Oncology) regarding AI-driven Drug Discovery for Gastrointestinal Tumor.

### **About Joint Research:**

Under the collaboration, Tokushima University, Department of Gastroenterology and Oncology that has an organoid cell established from pathological and tumor tissue taken from patients with the rare gastrointestinal tumor, and SOCIUM Inc. which has a unique AI-driven drug discovery platform Compound-Eyes™, Drug Saver™, Cyber-Drug-Discovery™ will collaborate to identify a novel drug candidate for the rare gastrointestinal tumor. In addition, we will consider the possibility of conducting the clinical study depending on the efficacy of drug candidates using organoids. We will combine the cutting-edge technologies of both teams to discover the therapeutic agent for patients with no drug, drug discovery for patients with ineffective drug in this joint research.

### **About Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences:**

The department researches on the mechanisms of gastrointestinal tumor and its progression, as well as on cancer therapy by targeting various specific molecules of tumor cells. has an organoid cell established from pathological and tumor tissue taken from patients with the rare

gastrointestinal tumor, and it is working on the analysis of drug resistance mechanism in gastrointestinal tumor.

**About SOCIUM Inc.:**

SOCIUM Inc. is the AI-powered, gene expression-inspired technology company pioneering the next generation of drug discovery. Its technology identifies new disease indications, especially rare diseases with high unmet needs that could be treated by your proprietary assets. The company also has an own development portfolio of over 23 diseases in the discovery stage, including oncology and rare diseases. The company is open to working with other pharmaceutical / biotech companies to expand the impact of their own pipeline assets.

Our research paper: <https://socium.co.jp/achievements/>

**Media Inquiries**

SOCIUM Inc.

AIST Tokyo Waterfront BIO-IT Research Building,

2-4-7, Aomi, Koto-ku, Tokyo 135-0064, JAPAN

Masaki Oka, Director, Corporate administrator

E-mail: [contact@socium.co.jp](mailto:contact@socium.co.jp)

Web: <https://socium.co.jp/>

TEL: +81(0)3-6869-7996